Nuveen
AGL icon

Nuveen’s Agilon Health AGL Stock Holding History

Nuveen’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.6M Buy
229,071
+197,075
+616% +$12.9M 0.01% 1136
2026
Q1 		$253K Buy
31,996
+161
+0.5% +$2.6K ﹤0.01% 3040
2025
Q4 		$548K Sell
31,835
-90,765
-74% -$1.76M ﹤0.01% 2836
2025
Q3 		$3.16M Buy
122,600
+9,938
+9% +$375K ﹤0.01% 2117
2025
Q2 		$6.48M Sell
112,662
-46,617
-29% -$3.74M ﹤0.01% 1751
2025
Q1 		$76.7M Buy
159,279
+126,614
+388% +$11M 0.02% 475
2024
Q4 		$1.55M Sell
32,665
-38,123
-54% -$2.3M ﹤0.01% 2490
2024
Q3 		$6.95M Buy
70,788
+27,737
+64% +$3.58M ﹤0.01% 1823
2024
Q2 		$7.04M Sell
43,051
-5,101
-11% -$727K ﹤0.01% 1771
2024
Q1 		$7.34M Buy
48,152
+8,244
+21% +$1.37M ﹤0.01% 1780
2023
Q4 		$12.5M Buy
39,908
+7,455
+23% +$2.7M ﹤0.01% 1446
2023
Q3 		$14.4M Buy
32,453
+2,346
+8% +$1.06M 0.01% 1255
2023
Q2 		$13.1M Buy
30,107
+8,783
+41% +$4.94M ﹤0.01% 1342
2023
Q1 		$12.7M Buy
21,324
+1,079
+5% +$604K ﹤0.01% 1337
2022
Q4 		$8.17M Sell
20,245
-108
-0.5% -$50.6K ﹤0.01% 1623
2022
Q3 		$11.9M Buy
20,353
+109
+0.5% +$65.3K ﹤0.01% 1363
2022
Q2 		$11M Buy
20,244
+1,444
+8% +$730K ﹤0.01% 1437
2022
Q1 		$10.8M Buy
18,800
+321
+2% +$165K ﹤0.01% 1590
2021
Q4 		$12.5M Buy
18,479
+11,501
+165% +$7M ﹤0.01% 1557
2021
Q3 		$5.06M Buy
6,978
+1,192
+21% +$1.02M ﹤0.01% 2204
2021
Q2 		$5.87M Buy
+5,786
New +$5.07M ﹤0.01% 2169

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen's AGL Position: Q2 2026 in Review

Nuveen increased its Agilon Health (AGL) stake by 616% in Q2 2026, buying an estimated $12.9M and bringing the position to 229,071 shares worth $24.6M. The position accounts for 0.01% of the portfolio, ranked #1136.

Nuveen first reported a position in AGL in Q2 2021 and has held it in 21 quarters since. The position peaked at $76.7M in Q1 2025. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • Nuveen held 229,071 shares of Agilon Health worth $24.6M as of Q2 2026.
  • Nuveen bought 197,075 Agilon Health shares in Q2 2026, an estimated $12.9M.
  • Agilon Health made up 0.01% of Nuveen's portfolio in Q2 2026, its #1136 holding.
  • Nuveen first reported a position in Agilon Health in Q2 2021 and has held it in 21 quarters since.
  • Nuveen's Agilon Health position peaked at $76.7M in Q1 2025.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.